Follitropin Delta in Long GnRH-agonist Protocol

NCT06995261 | Recruiting

• 1 other identifier: 2025-123 EC Luebeck
• Study Type: observational
• Target: 350
• Locations: 1 country
• Sites: 4

Brief Summary

The REWAG study ("Real-world Evaluation of Women undergoing Agonist protocol with Follitropin delta") is a non-interventional observational study conducted across several fertility centers in Germany. The goal of this study is to evaluate how well a personalized dosing regimen of a hormone called Follitropin delta works in women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) using a long GnRH agonist protocol. Follitropin delta is a recombinant follicle-stimulating hormone (rFSH) that allows for individualized dosing based on a woman's weight and a blood marker called anti-Müllerian hormone (AMH). This personalized approach may help to better balance the stimulation of the ovaries, aiming to reduce the risk of overstimulation (OHSS) while still achieving good treatment outcomes. The study will include approximately 350 women who are undergoing routine IVF/ICSI treatment. No experimental drugs or procedures are involved. All treatment decisions remain the responsibility of the attending physicians and follow standard clinical practice. Data will be collected only from routine visits and medical documentation, with no additional interventions required for participation. Researchers will analyze outcomes such as the number of eggs retrieved, pregnancy rates, treatment cancellations, and any side effects. The study will also look at whether certain patient characteristics can predict how well the treatment works or whether complications may arise. Participation is voluntary. All personal data will be pseudonymized and handled according to strict data protection regulations (GDPR). Results will help to improve understanding of how personalized hormone dosing performs in real-life settings and may support more tailored and effective fertility treatments in the future.

Conditions

Infertility (IVF Patients); Infertility; Infertility Drugs

Keywords

follitropin delta; Rekovelle; Long GnRH-agonist protocol; individualized ovarian stimulation; Dosing algorithm; FSH

Outcome Measures

Primary Outcomes (1)

• Ovarian Hyperstimulation Syndrome (OHSS)

  Ovarian Hyperstimulation Syndrome (OHSS) of any grade and any onset by Golan classification

  From oocyte pick-up to gestational week 20

Study Arms (1)

Follitropin Delta in Long GnRH Agonist Protocol

This cohort includes women undergoing controlled ovarian stimulation for IVF or ICSI treatment using Follitropin delta administered in a long GnRH agonist protocol. The dosing is individualized based on AMH serum levels and body weight. Participants are treated according to routine clinical practice, and no study drug is provided. The study is non-interventional.

Eligibility Criteria

• Age: 18 Years - 44 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Infertile women undergoing IVF oder ICSI. This study is intended to be conducted in non-vulnerable population. No vulnerable subjects will be enrolled in the study.

You may qualify if:

• Age ≥18 to ≤ 44 years at enrolment
• Planned stimulation in a long luteal GnRH agonist protocol with daily s.c. GnRH-agonist
• Planned use of Fd for ovarian stimulation as per SmPC
• Serum AMH ≥0.3 ng/ml to ≤4.9 ng/ml measured within12 months prior to treatment
• Most recent serum AMH value before start of stimulation not older than 12 months
• Planned IVF or ICSI treatment in a first or second attempt with ejaculated or cryopreserved male germ cells, autologous or heterologous, with or without planned genetic testing of the oocytes or embryos
• Planned triggering of final oocyte maturation with hCG
• Willingness and consent to participate

You may not qualify if:

• Serum AMH value not determined in ELECSYS AMH Plus Immunoassay, ACCESS AMH Advanced (Beckham Coulter) or LUMIPULSE G AMH (Fujirebio)
• Most recent serum AMH value before start of stimulation older than 12 months
• Serum AMH within 12 months prior to treatment AMH ≤ 0.3 ng/ml or ≥4.9 ng/ml measured within 12 months prior to treatment
• Pre-treatment with a combined oral contraceptive "pill" consisting of ethinyl estradiol and a synthetic progestogen or a natural estradiol/progesterone
• Anovulatory PCOS syndrome
• Women with a contraindication for prescription of Fd treatment
• Women undergoing ovarian stimulation for fertility preservation

Sponsors & Collaborators

• Prof. Dr. med. M.Sc. Georg Griesinger: lead
• University Hopsital Schleswig Holstein Campus Lübeck: collaborator

Study Sites (4)

Department of Obstetrics, Gynecology and Reproductive Endocrinology (UniKiD), Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf

Düsseldorf, North Rhine-Westphalia, 40225, Germany

RECRUITING

Center for Reproductive Medicine, IVF SAAR

Saarbrücken, Saarland, 66113, Germany

RECRUITING

Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus Kiel

Kiel, Schleswig-Holstein, 24105, Germany

RECRUITING

Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus Lübeck

Lübeck, Schleswig-Holstein, 23538, Germany

RECRUITING

Related Publications (1)

• Lobo R, Soerdal T, Ekerhovd E, Cohlen B, Porcu E, Schenk M, Shufaro Y, Smeenk J, Suerdieck MB, Pinton P, Pinborg A; BEYOND Investigators. BEYOND: a randomized controlled trial comparing efficacy and safety of individualized follitropin delta dosing in a GnRH agonist versus antagonist protocol during the first ovarian stimulation cycle. Hum Reprod. 2024 May 9;39(7):1481-94. doi: 10.1093/humrep/deae092. Online ahead of print.

  PMID: 38723189 BACKGROUND

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital Diseases; Urogenital Diseases

Central Study Contacts

Georg Griesinger, MD

CONTACT

+49 451 505 778 212; georg.griesinger@uni-luebeck.de

Lilit Kamalyan, MD, PhD

CONTACT

+49 451 505 778 212; Lilit.Kamalyan@uksh.de

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of Gynecological Endocrinology and Reproductive Medicine, Director, IVF Center, University of Lübeck / UKSH

Study Record Dates

• First Submitted: May 20, 2025
• First Posted: May 29, 2025
• Study Start: July 9, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: July 29, 2025

Record last verified: 2025-07

Locations

DE (4)